The nation of Zimbabwe has turned down a major US healthcare agreement worth 367 million US dollars (272 million pounds) spanning five years because of Washington's insistence on confidential information.
This rejection came to light following a government memo from December was leaked, which showed Head of State Emmerson Mnangagwa felt the deal was "lopsided".
A government spokesperson has since clarified that the US was seeking health data for scientific study and commercial purposes but was unwilling to share the benefits from future medical innovations.
"We will now turn to the difficult and regrettable task of scaling back our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the US had furnished more than $1.9bn for health programmes to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has urged more negotiations to reach a agreement acceptable to both sides so the country's vital HIV treatment initiative can be sustained.
Broader Background
This rejection follows a comparable case in Kenya, where a court halted a similar health funding agreement after concerns were raised about the security of Kenyans' health data.
After resuming office recently, US President Donald Trump has drastically cut overseas assistance and closed the US Agency for International Development (USAID).
The agency had administered aid for the US government, but Trump stated its spending was "inefficient" and his government was pursuing direct bilateral agreements to enhance openness and accountability.
Based on reports, Sixteen nations in Africa have so far agreed to similar health pacts, representing more than $18.3bn of fresh investment.
Specifics of the Rejected Deal
The funds for Zimbabwe would have funded "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this collaboration would have delivered extraordinary advantages for the people of Zimbabwe, especially the 1.2 million currently receiving antiretroviral therapy via American-funded programmes," the Ambassador commented.
However, official spokesman Nick Mangwana argued the arrangement was "unfair".
"Our nation was requested to surrender its genetic material and health information over an extended period, with no corresponding promise of access to any medical innovations – such as vaccines, diagnostics, or treatments – that might be developed from that provided information," his statement read.
"Put simply, our nation would provide the raw materials for scientific discovery with no assurance that the resulting innovations would be accessible to our citizens if a future disease outbreak arise."
National Interest and Global Health
He also said that the American exit from the global health body and its pursuit of bilateral health agreements were upending frameworks previously set up via the global health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme designed to manage potential global health emergencies.
"This mechanism is designed to guarantee that when a country provides its samples, the benefits – including medicines and cures – are shared equitably, not commercialised solely by those with the funds to create them."
The government's concerns regarding the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We encourage ongoing dialogue with our US partners on how subsequent co-operation might be designed in a way that respects the independence and dignity of each country."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it recognised the government's concerns, but recommended that negotiations should continue considering much of the nation's Aids initiatives relied on foreign aid.
"If specific concerns arise, including those involving data governance or agreement terms, these can often be addressed through technical clarification and mutually agreed protections," it said.
The halted deal highlights the complex tensions between accepting crucial foreign assistance and protecting local interests in an increasingly data-driven world.